期刊文献+

替加环素体外药敏试验操作规程专家共识 被引量:133

原文传递
导出
摘要 替加环素是一种甘氨酰环素类抗生素,于2005年在美国批准上市,全球共有50多个国家和地区批准和上市了替加环素,2012年初在中国批准上市。目前批注的适应证:(1)复杂性皮肤和皮肤软组织感染;(2)复杂性腹腔内感染;(3)社区获得性细菌性肺炎。南于替加环素具有广谱、抗菌活性强的特点,对于临床常见多重耐药菌感染有非常好的疗效,且临床使用方便,不需根据肾功能受损情况调整剂量,因此该抗菌药物将会在临床抗感染治疗中被广泛使用。
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2013年第7期584-587,共4页 Chinese Journal of Laboratory Medicine
基金 国家自然科学基金(31170125) 高等学校博士学科点专项科研基金(博导类)课题(20110001110043)
  • 相关文献

参考文献13

  • 1王辉,倪语星,陈民钧,胡必杰,王明贵,陈佰义,胡继红,胡云建.新型甘氨酰环素类抗菌药物替加环素的体外药敏试验操作规程[J].中华检验医学杂志,2009,32(11):1208-1213. 被引量:65
  • 2Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. MI00-S22. Wayne, PA:CLSI,2012.
  • 3European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version I. I, 2010-04-27.
  • 4Jones RN, Ferraro MJ, Reller LB, et al. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.J Clin Microbiol,2007 ,45 :227-230.
  • 5Fernrindez-Mazarrasa C, Mazarrasa 0, CalvoJ, et al. High concerntration of mananese in Mueller-Hinton agar increase MICs of tigecyc:line determined by Etest.J Clin Microbiol, 2009, 47: 827-829.
  • 6张冀霞,赵春江,刘文云,严薇,彭秋生,王占伟,王辉.替加环素对鲍曼不动杆菌和肺炎克雷伯菌体外抗菌活性检测的影响因素和方法学评估[J].中华检验医学杂志,2013,36(7):604-609. 被引量:23
  • 7Bradford PA, Petersen PJ, Young M, et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother ,2005,49 :3903-3909.
  • 8Curcio D, Fernandez F. Comment on: Effect of different Mueller?Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.J Antimicrob Chemother ,2008,62: 1166-1167.
  • 9杜小幸,王海萍,傅鹰,陈衍,俞云松.不同药敏方法检测替加环素对鲍曼不动杆菌敏感性的比较[J].中华检验医学杂志,2013,36(7):598-603. 被引量:22
  • 10Casal M, Rodriguez F,Johnson B, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-nan-susceptible Acinetobacter spp.J Antimicrob Chemather, 2009, 64:69-72.

二级参考文献48

  • 1Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother, 1999, 43:738-744.
  • 2Bradford P. Tigecycline: a first in class glycylcycline. Clin Micro Newsl, 2004,26:163-168.
  • 3Felmingham D. Tigecycline-the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline. J Chemother, 2005,17 Suppl 1:5-11.
  • 4Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother,1992 ,29 :245-277.
  • 5Schnappinger D, Hillen W. Tetraeyclines: antibiotic action, uptake, and resistance mechanisms. Arch Mierobiol, 1996, 165:359-369.
  • 6Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drugdirected Fe^2 + cleavage of 16S rRNA. J Antimicrob Chemother, 2004, 53:592-599.
  • 7Olson MW, Ruzin A, Feyfant E, et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother, 2006,50 : 2156 -2166.
  • 8Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Mierob Drug Resist, 2007,13:1-6.
  • 9Ruzin A, Visalli MA, Keeney D, et al. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother,2005,49 : 1017-1022.
  • 10Visalli MA, Murphy E, Projan SJ, et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline ( GAR- 936) in Proteus mirabilis. Antimicrob Agents Chemother. 2003.47,665-669.

共引文献91

同被引文献723

引证文献133

二级引证文献2384

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部